Vyome Holdings, Inc. HIND
Vyome Holdings, Inc. (Nasdaq: HIND) is a dermatology drug developer. Its lead program, VT-1953, is in Phase 2 for signs and symptoms (malodor, pain) of malignant fungating wounds in advanced cancer. Its next catalyst on record is VT-1953: Type C meeting with FDA on pivotal clinical development program in malignant fungating wounds (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VT-1953 — Type C meeting with FDA on pivotal clinical development program in malignant fungating wounds (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VT-1953 | malignant fungating wounds (completed Phase 2 investigator-initiated trial; pre-IND, FDA written feedback received Q2 2026; pivotal study planned) | small molecule | Phase 2 |
| VB-1953 | moderate to severe acne (completed Phase 2; described as Phase 3-ready) | small molecule | Phase 2 |
| VT-1908 | steroid-sparing anterior uveitis (ophthalmic drops, repurposed immune modulator; pre-IND) | small molecule | Pre-clinical |
| JAK inhibitor assets (in-licensed from Impetis Biosciences, May 2026) | immune-inflammatory diseases (preclinical) | small molecule | Pre-clinical |
Recent results and decisions
- Feb 13, 2026met Investigator-initiated Phase 2 (15 patients) met primary endpoint of malodor reduction at Day 14 (p=0.0020 vs baseline; p=0.0015 vs vehicle); no TEAEs reported.
VT - 1953 achieved a significant improvement (P=0.002) in the primary endpoint of malodor on Day 14 vs baseline as scored by investigators.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.